Kintu K, Malaba T, Nakibuka J, et al. RCT of Dolutegravir vs Efavirenz-based therapy initiated in late pregnancy: DOLPHIN-2. CROI 2019, abstract 40-LB.
Bulevirtide veelbelovend tegen hepatitis D, maar nog veel vragen
jul 2021 | Hepatitis, Hepatologie